These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3812030)

  • 1. Long-term corticosteroid treatment in giant cell arteritis.
    Andersson R; Malmvall BE; Bengtsson BA
    Acta Med Scand; 1986; 220(5):465-9. PubMed ID: 3812030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids.
    Bengtsson BA; Malmvall BE
    Acta Med Scand; 1981; 209(5):337-45. PubMed ID: 7246269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
    Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
    Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymyalgia rheumatica and corticosteroids: how much for how long?
    Behn AR; Perera T; Myles AB
    Ann Rheum Dis; 1983 Aug; 42(4):374-8. PubMed ID: 6882032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of blindness in giant cell arteritis by corticosteroid treatment.
    Myles AB; Perera T; Ridley MG
    Br J Rheumatol; 1992 Feb; 31(2):103-5. PubMed ID: 1737222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):662-6. PubMed ID: 2782976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis.
    Hachulla E; Boivin V; Pasturel-Michon U; Fauchais AL; Bouroz-Joly J; Perez-Cousin M; Hatron PY; Devulder B
    Clin Exp Rheumatol; 2001; 19(2):171-6. PubMed ID: 11326479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1993 Dec; 52(12):847-50. PubMed ID: 8311533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral content of the third lumbar vertebra during 18 months of prednisolone treatment for giant cell arteritis.
    Nordborg E; Hansson T; Jonson R; Szücs J; Bengtsson BA
    Clin Rheumatol; 1993 Dec; 12(4):455-60. PubMed ID: 8124904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis.
    García-Martínez A; Hernández-Rodríguez J; Grau JM; Cid MC
    Arthritis Rheum; 2004 Aug; 51(4):674-8. PubMed ID: 15334444
    [No Abstract]   [Full Text] [Related]  

  • 11. An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis.
    Bengtsson BA; Malmvall BE
    Acta Med Scand; 1981; 209(5):347-50. PubMed ID: 7246270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 26-week feasibility study comparing the efficacy and safety of modified-release prednisone with immediate-release prednisolone in newly diagnosed cases of giant cell arteritis.
    Raine C; Stapleton PP; Merinopoulos D; Maw WW; Achilleos K; Gayford D; Mapplebeck S; Mackerness C; Schofield P; Dasgupta B
    Int J Rheum Dis; 2018 Jan; 21(1):285-291. PubMed ID: 28791802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
    Spiera RF; Mitnick HJ; Kupersmith M; Richmond M; Spiera H; Peterson MG; Paget SA
    Clin Exp Rheumatol; 2001; 19(5):495-501. PubMed ID: 11579707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study of 90 patients treated with corticosteroids.
    Andersson R; Malmvall BE; Bengtsson BA
    Acta Med Scand; 1986; 220(4):361-4. PubMed ID: 3799241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy].
    Hatz HJ; Helmke K
    Z Rheumatol; 1992; 51(5):213-21. PubMed ID: 1476006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual performance in giant cell arteritis (temporal arteritis) after 1 year of therapy.
    Kupersmith MJ; Langer R; Mitnick H; Spiera R; Spiera H; Richmond M; Paget S
    Br J Ophthalmol; 1999 Jul; 83(7):796-801. PubMed ID: 10381666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.
    Jover JA; Hernández-García C; Morado IC; Vargas E; Bañares A; Fernández-Gutiérrez B
    Ann Intern Med; 2001 Jan; 134(2):106-14. PubMed ID: 11177313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
    Kyle V; Hazleman BL
    Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Corticosteroid saving-up in giant cell arteritis?].
    Schnabel A
    Dtsch Med Wochenschr; 2002 Sep; 127(37):1910. PubMed ID: 12226792
    [No Abstract]   [Full Text] [Related]  

  • 20. [Natural history of corticosteroid-induced lipodystrophy: a prospective follow-up of 37 patients].
    Fardet L; Flahault A; Kettaneh A; Tiev KP; Tolédano C; Cabane J
    Rev Med Interne; 2007 Dec; 28(12):825-31. PubMed ID: 17959276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.